You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

346 Results
Drug
Other Name(s): Yervoy®
Aug 2024
Guidelines and Advice
Status: Current
ID: 4-16
Version: 2
Updated
May 2025
Les fiches d’information sur les soins palliatifs pour les Autochtones sont élaborées afin de soutenir les membres des Premières Nations, des Inuits...
The Indigenous Palliative Care Fact Sheets are developed to support First Nations, Inuit, Métis and urban Indigenous people living with a life-...
Drug
Other Name(s): Imbruvica®
Updated
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria
Updated
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
Updated
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, as monotherapy, based on criteria
Updated
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Palliative
Updated
Jun 2025

Pages